Press release
Pulmonary Fibrosis Treatment Market Size Report 2032: Major Companies, Emerging Drugs, Clinical Trials, MOA, FDA Approvals | DelveInsight
Pulmonary Fibrosis Market
Discover Key Insights into the Pulmonary Fibrosis Market with DelveInsight's In-Depth Report @ Pulmonary Fibrosis Market Size- https://www.delveinsight.com/sample-request/pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Pulmonary Fibrosis Market Report
• In February 2025:- GlaxoSmithKline:- Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
• The leading Pulmonary Fibrosis companies such as MediciNova Inc., Jubilant Pharma Limited, Merck & Co. Inc., Horizon Therapeutics Inc., United Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., Avalyn Pharma Inc., CS Pharmaceuticals, and others
• Promising Pulmonary Fibrosis Therapies such as BMS-986278, Pirfenidone, Etanercept, n-acetylcysteine, BI 1015550, and others.
Stay ahead in the Pulmonary Fibrosis Therapeutics Market with DelveInsight's Strategic Report @ Pulmonary Fibrosis Market Outlook- https://www.delveinsight.com/sample-request/pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Pulmonary Fibrosis Epidemiology Segmentation in the 7MM
• Total Pulmonary Fibrosis Prevalent Cases
• Total Pulmonary Fibrosis Diagnosed Cases of Birch allergy,
• Total Pulmonary Fibrosis Treated Cases
Download the report to understand which factors are driving Pulmonary Fibrosis epidemiology trends @ Pulmonary Fibrosis Prevalence=- https://www.delveinsight.com/sample-request/pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Pulmonary Fibrosis Market Outlook
The Pulmonary Fibrosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pulmonary Fibrosis market trends by analyzing the impact of current Pulmonary Fibrosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology. According to DelveInsight, the Pulmonary Fibrosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Pulmonary Fibrosis Drugs Uptake
The drug chapter segment of the Pulmonary Fibrosis report encloses the detailed analysis of Pulmonary Fibrosis marketed drugs and late-stage (Phase-III and Phase-II) Pulmonary Fibrosis pipeline drugs. It also helps to understand the Pulmonary Fibrosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Get In-Depth Knowledge on Pulmonary Fibrosis Market Trends and Forecasts with DelveInsight @ Pulmonary Fibrosis Treatment Market- https://www.delveinsight.com/sample-request/pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Pulmonary Fibrosis Market Report
• Coverage- 7MM
• Pulmonary Fibrosis Companies- MediciNova Inc., Jubilant Pharma Limited, Merck & Co. Inc., Horizon Therapeutics Inc., United Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., Avalyn Pharma Inc., CS Pharmaceuticals, and others
• Pulmonary Fibrosis Therapies- BMS-986278, Pirfenidone, Etanercept, n-acetylcysteine, BI 1015550, and others.
• Pulmonary Fibrosis Market Dynamics: Pulmonary Fibrosis Market Drivers and Barriers
• Pulmonary Fibrosis Market Access and Reimbursement, Unmet Needs, and Future Perspectives
Unlock Strategic Insights with DelveInsight's Comprehensive Pulmonary Fibrosis Market Report @ Pulmonary Fibrosis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Executive Summary of Pulmonary Fibrosis
3. Competitive Intelligence Analysis for Pulmonary Fibrosis
4. Pulmonary Fibrosis: Market Overview at a Glance
5. Pulmonary Fibrosis: Disease Background and Overview
6. Patient Journey
7. Pulmonary Fibrosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Pulmonary Fibrosis Unmet Needs
10. Key Endpoints of Pulmonary Fibrosis Treatment
11. Pulmonary Fibrosis Marketed Products
12. Pulmonary Fibrosis Emerging Therapies
13. Pulmonary Fibrosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Pulmonary Fibrosis
17. KOL Views
18. Pulmonary Fibrosis Market Drivers
19. Pulmonary Fibrosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Fibrosis Treatment Market Size Report 2032: Major Companies, Emerging Drugs, Clinical Trials, MOA, FDA Approvals | DelveInsight here
News-ID: 4127271 • Views: …
More Releases from DelveInsight Business Research LLP
Colorectal Cancer Pipeline Drugs in Development Signal Major Shifts in the Treat …
DelveInsight's, "Colorectal Cancer Pipeline Insight 2025" report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Colorectal…
Idiopathic Pulmonary Fibrosis Pipeline Clinical Trial Insights Reveal Breakthrou …
DelveInsight's, "Idiopathic Pulmonary Fibrosis Pipeline Insights 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Idiopathic Pulmonary Fibrosis pipeline products in this…
Small Cell Lung Cancer Pipeline Clinical Trials Highlight Promising Drugs in Dev …
DelveInsight's, "Small Cell Lung Cancer Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
Myelofibrosis Pipeline Outlook 2025: Insights Into Therapies, Research, and Mark …
DelveInsight's, "Myelofibrosis Pipeline Insights 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis Pipeline…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
